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Abstract
Background: Previous studies mention the use of topical acyclovir for the treatment of equine sarcoids. Success
rates vary and since the bovine papillomavirus (BPV) lacks the presence of a kinase necessary to activate acyclovir,
there is no proof of its activity against equine sarcoids.
Results: Twenty-four equine sarcoids were topically treated with acyclovir cream and 25 with a placebo. Both
creams were applied twice daily during 6 months. Before the start of the treatment and further on a monthly basis,
photographs and swabs were obtained. On the photographs, sarcoid diameter and surface area were measured
and verrucosity of the tumours was quantified using a visual analog scale (VAS). The swabs were analysed by PCR
for the presence of BPV DNA and positivity rates were calculated as the number of positive swabs divided by the
total number of swabs for each treatment group at each time point. Success rates were not significantly different
between both treatment groups. There was also no significant effect of treatment on sarcoid diameter, surface area
or VAS score. For the swabs, a significantly higher BPV positivity rate was found for acyclovir treated tumours compared
to placebo treated sarcoids only after 1 month of treatment and not at other time points.
Conclusions: None of the results indicate that treatment with acyclovir yields any better results compared to placebo
treatment.
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Background
Acyclovir (acycloguanosine) is an antiviral drug devel-
oped for the treatment of herpes simplex virus (HSV)
infections in humans [1]. The drug relies on competitive
inhibition of the viral DNA polymerase, but needs to be
phosphorylated by a HSV specific thymidine kinase and
then further by cellular enzymes to a triphosphate form
to exert its action [2]. Nevertheless, inhibition of viral
replication also occurs for other viral species then HSV
[3], suggesting phosphorylation of the drug may also
occur in cells where the HSV thymidine kinase is not
present, albeit to a lesser extent.
Equine sarcoids are tumours originating in the dermal
layers of equine skin. The pathogenesis is not entirely
clear yet, but there is agreement in literature that the bo-
vine papillomavirus (BPV) (mainly type 1 and type 2)
most likely plays an important role in the development
of these tumours [4]. Many treatments have been re-
ported, but no universal treatment has been found to
cure all sarcoids on all body locations.
Topical treatment with acyclovir has been described to
result in complete regression in 68% of occult, verrucous,
nodular or mixed equine sarcoids [5]. In addition, a recent
ex vivo study has shown that acyclovir concentrations
reached in the dermal layers after topical administration
on sarcoid-affected equine skin are high enough to possibly
achieve an antiviral effect [6]. However, the thymidine kin-
ase necessary for initial phosphorylation of the drug is
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missing in BPV DNA [7] and the susceptibility of the BPV
DNA polymerase for acyclovir is unknown. A retrospective
study further described complete regression after topical
acyclovir treatment in only 53% of the cases [8].
The goal of the present study was to establish if topical
treatment of occult equine sarcoids with a 5% acyclovir
cream is more effective compared to the application of a
placebo cream following the same administration protocol.
Methods
Subjects
A power analysis revealed that at least 15 unrelated sar-
coids were needed in each treatment group to be able to
show a difference between acyclovir and placebo treat-
ments (power = 0.8; type-1 error = 0.05). Because mul-
tiple sarcoids on the same horse would be treated the
same way, a minimum of 15 horses was necessary in
each treatment group.
All horses that were presented to the Department of
Surgery and Anaesthesiology of the Faculty of Veterinary
Medicine of Ghent University for the treatment of previ-
ously untreated occult or partly verrucous equine sar-
coids were considered for inclusion in the study. Horses
that had fibroblastic or nodular sarcoids in addition to
the occult and/or partly verrucous tumours and horses
that received concurrent medical treatment for other in-
dications were excluded. The diagnosis of equine sarcoid
was made by clinical examination by an experienced vet-
erinarian. As a compensation for taking part in the
study, the treatments and consultations were offered free
of charge and sarcoids that would have been treated with
placebo during the study would be treated afterwards
without additional costs. When owners were willing to
participate, an informed consent was signed in which
the owners also committed to apply the topical treat-
ment as instructed.
Treatment and sampling
Sarcoids were topically treated with either a generic 5%
acyclovir cetomacrogol cream or a placebo consisting of
the same cetomacrogol cream without active compo-
nent. The choice between both treatments was made at
random and owners were blinded to the treatment.
Packaging of the creams was identical and the labels
were coded. When multiple occult or partly verrucous
sarcoids were present on the same horse, all tumours
were treated with the same product.
The sarcoids of both treatment groups were com-
pletely covered with cream twice daily by the owner. If
cream remnants were still present, the lesion was
cleaned with water and dried with a paper towel before
applying more. Owners were instructed and demon-
strated to beforehand how to apply the cream. Treat-
ment continued for 6 months or until the sarcoid had
disappeared completely. The experiment was stopped if
sudden aggressive growth of the sarcoid would occur.
Before the start of the treatment (T0) and further at
monthly intervals (T1 until T6), a close-up photograph
of the sarcoid was taken with a ruler next to, but not
covering the tumour. To gain more insight in the anti-
viral effect of acyclovir on BPV in equine sarcoids, a
swab sample for BPV DNA analysis was taken at the
same time as the photographs by rubbing a sterile cot-
tontip swab soaked in sterile distilled water over the sur-
face of the sarcoid [9]. Swabs were stored in separate
containers at −20 °C until further processing. When the
horses were stabled too far away from the clinic, private
practitioners were responsible for obtaining the swab
samples and photographs and provide them to the clinic.
When this was the case, the private practitioners re-
ceived clear instructions on how to do this to ensure a
high sample quality.
All pictures and samples were processed together at
the end of the experiment. Pictures were given a random
coded file name and put in random order to ensure
blinded processing. On all pictures, sarcoid maximal
diameter and surface area were measured twice using
image measuring software (ImageJ). The mean of two
measurements was used for further analysis. Severity of
the sarcoid was determined by three diplomates of the
European College of Veterinary Surgeons. A visual ana-
log scale (VAS) was used ranging from no visible abnor-
malities of the skin (score 0) to distinct skin verrucosity
(score 1000) (Fig. 1). The mean of three scores was used
for further analysis.
Swabs were examined for the presence of BPV DNA.
DNA was extracted using a commercial kit (DNeasy
Blood & Tissue Kit, Qiagen). Swabs were first incubated
for 12 h in 180 μl buffer ATL and 20 μl proteinase K at
56 °C. The samples were then vortexed and 200 μl buffer
AL was added. After vortexing again, swabs were re-
moved from the vials and discarded. Further DNA ex-
traction was continued as described in the manual of the
kit, following the tissue protocol. After DNA extraction,
real-time PCR analysis was performed using general
BPV primers and BPV-1 and -2 specific TaqMan probes
as described by Bogaert et Al. [10]. All samples were
processed in duplicate and when quantification cycle
values between repeats differed by more than one, the
PCR was repeated. Positive controls consisting of a mix-
ture of known BPV-1 and BPV-2 samples and negative
controls consisting of distilled water were included in
each run. All samples were also tested for the presence
of equine interferon beta (IFNb) DNA to confirm suc-
cessful DNA extraction [11]. Samples were considered
positive when either BPV-1 or BPV-2 DNA was de-
tected. Samples were only considered negative when
IFNb DNA could be detected, but no BPV DNA. When
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no IFNb DNA was detected, samples were marked as
missing data for further analysis.
Statistical analysis
All data analysis was performed using statistical software
(SPSS 20, IBM). Statistical significance was set at
p ≤ 0.05. To estimate the effect of treatment on the
number of fully regressed sarcoids, a Fisher exact test
was used. For all continuous data (sarcoid diameter, sar-
coid surface area and VAS score), the effect of time and
treatment on the dependent variables was determined by
repeated measures ANOVAs with horse as a blocking
factor. When sphericity could not be assumed, a
Greenhouse-Geisser correction was applied. Addition-
ally, a “change parameter” was calculated for continuous
data from all sarcoids as the difference between the
measurement at T0 and the last measurement. The ef-
fect of treatment on this “change parameter” was esti-
mated by a generalized linear model, corrected for
follow-up time and with horse as a blocking factor. For
each time point, the effect of treatment on the number
of samples positive for BPV DNA was tested using a bin-
ary logistic regression with horse as a blocking factor.
To test the effect of time on the number of samples
positive for BPV DNA, a binary logistic regression with
horse as a blocking factor was used for both treatments
with T0 as the reference category.
Results
Twenty-eight horses and three ponies were included in
the study. In total, 24 sarcoids on 15 individuals were
treated topically with 5% acyclovir cream and 25 sar-
coids on 16 individuals were treated topically with pla-
cebo cream. Multiple sarcoids were present in four
horses in the acyclovir group, and in five horses in the
placebo group. For both groups, median treatment time
was 6 months (min: 1 month, max: 6 months). The
study was stopped early because of sudden aggressive
tumoural growth in one horse, which was part of the
acyclovir treatment group. For three placebo treated
horses and one acyclovir treated horse, the study was
stopped early because of complete sarcoid regression.
No side effects were observed in any of the treated
horses.
Complete regression during treatment occurred in two
of the acyclovir treated sarcoids (8.3%; 95% CI: 1.0% -
27.0%), while this was the case in four (16%; 95% CI:
4.5% - 36.1%) of the placebo treated sarcoid. This differ-
ence was not significant (p = 0.67).
Figure 2 shows the mean measurements along with
the 95% confidence interval of sarcoid diameter (A), sar-
coid surface (B) and VAS score (C) at each time point
for both treatment groups. The intraclass correlation co-
efficient of the raters for average measures of VAS was
77.0%. There was no significant effect of treatment or
time on any of these variables. The mean calculated
“change parameters” are listed in Table 1 along with the
p-values for the effect of treatment on them. A positive
“change parameter” indicates a decrease in measurement
between T0 and the last sample point whereas a negative
change indicates an increase. The mean largest sarcoid
diameter of acyclovir treated tumours increased during
treatment, while it decreased for the placebo treated sar-
coids (Table 1). Mean surface area increased during the
treatment for both groups (Table 1). Mean VAS score
decreased, indicating that sarcoids were found to be less
verrucous towards the end of the treatment (Table 1).
Differences in “change parameters” between both treat-
ment groups were never significant.
No genomic DNA was present on the swab in 15.9%
of the samples in the acyclovir treated group and in
22.8% of the samples in the placebo group. Figure 3
shows the percentage of positive PCR samples in each
treatment group at each time point. Only at T1, a sig-
nificantly higher percentage of samples was positive for
the presence of BPV DNA in the acyclovir group com-
pared to the placebo group (p = 0.005). At all other time
points, there were no significant differences between
groups. In the acyclovir group, the percentage of positive
samples was significantly higher at T1 compared to T0
Fig. 1 Example of how a slider bar was used to determine severity of a sarcoid on a visual analog scale (VAS), based on verrucosity
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Fig. 2 Mean measurements along with the 95% confidence interval of sarcoid diameter (a), sarcoid surface (b) and visual analog scale (VAS) score
(c) at each time point for both treatment groups
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(p = 0.004). At all other time points, the percentage of
positive samples was not significantly different from T0.
In the placebo group, the percentage of positive samples
was significantly lower at all time points except for T1,
compared to the percentage of positive samples at T0
(T2: p = 0.06; T3: p = 0.03; T4: p = 0.04; T5: p = 0.04;
T6: p = 0.04).
Discussion
This is the first study on equine sarcoid treatment which
is placebo controlled and double blinded. Results of this
study are therefore valuable for treatment selection in
practice. Because of the long study duration, the horses
were cared for by their owners at home and this impli-
cated that it was hard to check for treatment compliance.
However, all owners signed a commitment to the experi-
ment beforehand and were contacted regularly by phone
to monitor the course of the study. Because the horses
were stabled at home and this was in many cases too far
away to allow for visits to the clinic, monthly visits were
often performed by trusted private practitioners. While
this implicates a possible variation in sample quality, prac-
titioners received clear instructions on how to take pic-
tures and swabs to maximize uniformity. A benefit of this
was that the persons evaluating the pictures and analyzing
the samples never saw the patients in real life, which en-
abled an unprejudiced evaluation.
The success rate for acyclovir treatment was lower
compared to previously reported success rates [5, 8].
The sample population of the present study was smaller,
which could explain the lower success rates. Moreover,
acyclovir treatment was stopped after 6 months of treat-
ment in the present study, while under normal clinical
circumstances it is often continued longer when the
tumour has not fully regressed yet, but a beneficial effect
is observed. In both previous studies, a certain number
of sarcoids have indeed been treated for over 6 months,
which could have increased the success rate. While the
concentration of acyclovir in the cream used in the
present study was the same as in all earlier studies [5, 8],
the constitution of the cream vehicle used in this and
earlier studies by Haspeslagh et al. [6, 8] differed from
the one used by Stadler et al. [5].
Time and treatment type did not have a significant in-
fluence on mean sarcoid dimensions or mean VAS score.
Mean “change parameters” were also not significantly
different between treatment groups. Nevertheless, the
mean VAS score decreased for both treatment groups
during the study, indicating that equine sarcoids were
found less verrucous towards the end of the treatment.
Perhaps the previously observed benign effect is there-
fore not due to the application of acyclovir, but merely
to the effect of a cream that keeps the skin hydrated,
preventing the formation of a thick verrucous layer.
Anti-keratotic creams have analogously been used to
lessen the verrucosity of equine sarcoids prior to other
treatments [12]. This hypothesis can be tested by includ-
ing a third “no treatment” group, which was not done
here due to ethical considerations towards the owners.
The presence of a keratinous layer in equine sarcoids
with a high degree of verrucosity could interfere with
acyclovir penetration and the presence of highly verru-
cous tumours could have influenced the results. Never-
theless, the mean VAS score, based on verrucosity, was
Table 1 Mean “change parameters” and associated p-values for
the difference between both treatment groups (SE = Standard
Error; VAS = visual analog scale)
Change Acyclovir (± SE) Placebo (± SE) p-value
Diameter (mm) −6.10 (± 4.63) 2.02 (± 5.67) 0.52
Surface area (mm2) −314.26 (± 203.44) −60.25 (± 247.67) 0.87
VAS score 146.43 (± 53.75) 166.58 (± 39.41) 0.65
Fig. 3 The percentage of samples positive for the presence of BPV DNA at each time point (months after start of the treatment) and corresponding
95% confidence intervals. No fill: acyclovir; dotted fill: placebo
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not very high at T0 and decreased during treatment.
VAS scores at T0 did also not differ significantly be-
tween the acyclovir and placebo group, indicating that
the comparison between both groups is valid. To evalu-
ate the effect of a thick verrucous layer on acyclovir
treatment, a similar experiment could be performed
comparing treatment of strictly occult versus strictly ver-
rucous tumours.
In order to obtain a good indication of the BPV load
in non-ulcerated equine sarcoids, a quantitative real-
time PCR on tissue from a biopsy probably yields the
most reliable results. However, this would have required
the sarcoids to be biopsied prior to the study and further
at each time point of evaluation, which could have influ-
enced the outcome, as equine sarcoids often become
more aggressive after being damaged [13, 14]. For this
reason, swabs were obtained instead of biopsies. This
also implies that histological examination to confirm the
diagnosis of equine sarcoid could not be performed and
that there is a chance that some lesions which regressed
spontaneously were not actual equine sarcoids. Never-
theless, the clinical appearance of equine sarcoids is so
typical that clinical examination by an experienced veter-
inarian should be sufficient to make a correct diagnosis
[14, 15]. While the presence of BPV DNA can be shown
in up to 100% of swabs from equine sarcoids, this is only
the case in ulcerated tumours where the dermis is ex-
posed [9]. As this was never the case in this study, the
percentage of positive samples was lower and in range
with the earlier reported positivity rate originating from
occult sarcoids [9]. Nevertheless, in the placebo group, a
clear and significant decrease in the positivity rate could
be seen over time, which was not the case for acyclovir
treated tumours. No plausible explanation could be
given for this observation.
Conclusions
None of the results presented in this study indicate that
topical treatment of occult or partly verrucous equine
sarcoids with acyclovir yields any better results com-
pared to treatment with placebo cream.
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